Abstract
The heart is a target organ in antiphospholipid syndrome (APS). Endocardial disease, intracardiac thrombosis, myocardial involvement including coronary heart disease and microvascular thrombosis, as well as pulmonary hypertension have all been described in APS patients. Valvular involvement is the most common manifestation with a prevalence of 82% detected by transesophageal echocardiography. Symmetrical, nodular thickening of the mitral and/or aortic valves is characteristic. Anticoagulant/antiplatelet treatment is ineffective in terms of valvular lesion regression. Some patients require cardiac valve replacement. However, patients with APS have shown an increased perioperative morbidity and mortality. Intracardiac thrombosis, although a rare complication, can cause pulmonary and systemic emboli. Differential diagnosis with myxoma may be very difficult.
Similar content being viewed by others
References
Hughes GRV, Harris EN, Gharavi AE (1986) The anticardiolipin syndrome. J Rheumatol 13:486–489
Cervera R, Khamashta M, Font J et al (1991) High prevalence of significant heart valve lesions in patients with the “primary” antiphospholipid syndrome. Lupus 1:43–47
Galve E, Ordi J, Barquinero J et al (1992) Valvular heart disease in the primary antiphospholipid syndrome. Ann Intern Med 116:293–298
Badui E, Solorio S, Martínez E et al (1995) The heart in the primary antiphospholipid syndrome. Arch Med Res 26:115–120
Vianna JL, Khamashta MA, Ordi-Ros J et al (1994) Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med 96:3–9
Nesher G, Ilany J, Rosenmann D et al (1997) Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum 27:27–35
Espínola-Zavaleta N, Vargas-Barrón J, Colmenares T et al (1999) Echocardiographic evaluation of patients with primary antiphospholipid syndrome. Am Heart J 137:974–979
Turiel M, Muzzupappa S, Gottardi B, Crema C, Sarzi-Puttini P, Rossi E (2000) Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography. Lupus 9:406–412
Qaddoura F, Connolly H, Grogan M, Orszulak TA, Schaff HV, Chandrasekaran K, Click RL (2005) Valve morphology in antiphospholipid antibody syndrome: echocardiographic features. Echocardiography 22:255–259
Espínola-Zavaleta N, Amigo MC, Vargas-Barrón et al (2001) Two- and three-dimensional echocardiography in primary antiphospholipid syndrome: misdiagnosis as rheumatic valve disease. Lupus 10:511–513
Turiel M, Sarzi-Puttini P, Peretti R et al (2005) Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. Am J Cardiol 96:574–579
García-Torres R, Amigo MC, de la Rosa A et al (1996) Valvular heart disease in primary antiphospholipid syndrome (PAPS): clinical and morphological findings. Lupus 5:56–61
Ziporen L, Goldberg I, Arad MY et al (1996) Libman–Sacks endocarditis in the antiphospholipid syndrome; immunopathologic findings in deformed heart valves. Lupus 5:196–205
Afek A, Shoenfeld Y, Manor R et al (1999) Increased endothelial cell expression of α3β1 integrin in cardiac valvulopathy in the primary (Hughes) and secondary antiphospholipid syndrome. Lupus 8:502–507
Espínola-Zavaleta N, Montes RM, Soto ME, Avila Vanzzini A, Amigo MC (2004) Primary antiphospholipid syndrome: a 5-year transesophageal echocardiographic followup study. J Rheumatol 31:2402–2407
Petri M (2004) Classification criteria for antiphospholipid syndrome: the case for cardiac valvular disease. J Rheumatol 31:2329–2330
Agirbasli MA, Hansen DE, Byrd BF (1997) Resolution of vegetations with anticoagulation after myocardial infarction in primary antiphospholipid syndrome. J Am Soc Echocardiogr 10:877–880
Nesher G, Ilany J, Rosenmann D, Abraham AS (1997) Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum 27:27–35
Hojnik M, George J, Ziporen L, Shoenfeld Y (1996) Heart valve involvement (Libman–Sacks endocarditis) in the antiphospholipid syndrome. Circulation 93:1579–1587
Lockshin M, Tenedios F, Petri M, Mc Carty G, Forastiero R, Krilis S et al (2003) Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus 12:518–523
Tenedios F, Erkan D, Lockshin MD (2005) Cardiac involvement in the antiphospholipid syndrome. Lupus 14:691–696
Erkan D, Yazici Y, Sobel R, Lockshin MD (2000) Primary antiphospholipid syndrome: functional outcome after 10 years. J Rheumatol 27:2817–2821
Yoshida M, Sasako Y, Kobayashi J et al (2000) Mitral valve plasty in systemic lupus erythematosus in the setting of antiphospholipid syndrome. Jpn J Thorac Cardiovasc Surg 48:391–393
Myerowitz PD, Michaelis LL, McIntosh CL (1974) Mitral valve replacement for mitral regurgitation due to Libman–Sacks endocarditis. J Thorac Cardiovasc Surg 67:869–874
Dajee H, Hurley EJ, Szarnicki RJ (1983) Cardiac valve replacement in systemic lupus erythematosus. J Thorac Cardiovasc Surg 85:718–726
Hakim JP, Mehta A, Jain AC, Murray GF (2001) Mitral valve replacement and repair. Report of 5 patients with systemic lupus erythematosus. Texas Heart Inst J 28:47–52
Vaughton KC, Walker DR, Sturridge MF (1979) Mitral valve replacement for mitral stenosis caused by Libman–Sacks endocarditis. Br Heart J 41:730–733
Ciocca RG, Choi J, Graham AM (1995) Antiphospholipid antibodies lead to increase risk in cardiovascular surgery. Am J Surg 170:198–200
Berkun Y, Elami A, Meir K, Mevorach D, Naparstek Y (2004) Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. J Thorac Cardiovasc Surg 127:414–420
Massoudy P, Cetin SM, Thiemann M et al (2005) Antiphospholipid syndrome in cardiac surgery—an underestimated coagulation disorder? Eur J Cardio-thorac Surg 28:133–137
Dornan RIP (2004) Acute postoperative biventricular failure associated with antiphospholipid antibody syndrome. Br J Anaesth 92:748–754
Erkan D, Leibowitz E, Berman J, Lockshin MD (2002) Perioperative management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendations. J Rheumatol 29:843–849
Sheikh F, Lechowics A, Setkur R, Rauch A, Dunn H (1997) Recognition and management of patients with antiphospholipid antibody syndrome undergoing cardiac surgery. J Cardiothorac Vasc Anesth 11:764–766
Hogan WJ, Mc Bane RD, Santrach PJ et al (2000) Antiphospholipid syndrome and perioperative hemostatic management of cardiac valvular surgery. Mayo Clin Proc 75:971–976
Ducart AR, Collard EL, Osselaer JC et al (1997) Management of anticoagulation during cardiopulmonary bypass in a patient with a circulating lupus anticoagulant. J Cardiothoracic Vasc Anesth 11:878–879
East CJ, Clements F, Mathew J, Slaughter TF (2000) Antiphospholipid syndrome and cardiac surgery: management of anticoagulation in two patients. Anesth Analg 90:1098–1101
Asherson RA, Gibson DG, Evans DW, Baguley E, Hughes GR (1988) Diagnostic and therapeutic problems in two patients with antiphospholipid antibodies, heart valve lesions, and transient ischemic attacks. Ann Rheum Dis 47:947–953
Font J, Cervera R (2000) Cardiac manifestations in the antiphospholipid syndrome. In: Khamashta MA (ed) Hughes Syndrome. The antiphospholipid syndrome. London, Springer-Verlag, pp 32–42
Pope JM, Canny CL, Bell DA (1991) Cerebral ischemic events associated with endocarditis, retinal vascular disease, and lupus anticoagulant. Am J Med 90:299–309
Barbut D, Borer JS, Gharavi A et al (1992) Prevalence of anticardiolipin antibody in isolated mitral or aortic regurgitation, or both, and possible relation to cerebral ischemic events. Am J Cardiol 70:901–905
Pamuk ON, Cakir N, Soy M, Aktoz M, Celik Y, Akdemir O (2003) Mitral valve vegetation and cerebral emboli in a primary antiphospholipid syndrome patient who had hepatitis C virus infection: report of a case and review of the literature. Clin Rheumatol 22:136–139
Erdogan D, Goren T, Diz-Kucukkaya R, Inanc M (2005) Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome. A transesophageal echocardiographic study. Stroke 36:592–596
Krause I, Lev S, Fraser A et al (2005) Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis 64:1490–1493
Leventhal LJ, Borofsky MA, Bergey PD, Schumacher HR Jr (1989) Antiphospholipid antibody syndrome with right atrial thrombosis mimicking an atrial myxoma. Am J Med 87:111–113
Brancaccio G, Di Gioia C, Prifti E, Dámati G, Michielon G, Miraldi F (2002) Antiphospholipid antibodies and intracardiac thrombosis. A case report. J Cardiovasc Surg (Torino) 43:479–482
Granel B, Garcia E, Serratrice J et al (1999) Asymptomatic intracardiac thrombi and primary antiphospholipid syndrome. Cardiology 92:65–67
Denie C, Lefebvre C, Dion R, Coche E (1994) Thrombus of the right atrium simulating myxoma in primary antiphospholipid syndrome. Rev Med Intern 15:409–411
Gertner E, Leatherman JW (1992) Intracardiac mural thrombus mimicking atrial myxoma in the antiphospholipid syndrome. J Rheumatol 19:1293–1298
Esteban E, Blanes A, Moreno MT, Cánovas SJ, Montero JA, Sotillo JF (2002) Mixoma auricular derecho en paciente con anticuerpos antifosfolipídicos positivos. Rev Esp Cardiol 55:999–1002
Erkan D, Erel H, Yazici Y, Prince MR (2002) The role of cardiac magnetic resonance imaging in antiphospholipid syndrome. J Rheumatol 29:2658–2659
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Amigo, MC. The Heart and APS. Clinic Rev Allerg Immunol 32, 178–183 (2007). https://doi.org/10.1007/s12016-007-0013-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-007-0013-z